180 Life Sciences Corporate Media Kit

32 Fibrosis Program Patents (cont’d) TREATMENT FOR DUPUYTREN’S DISEASE Country Application No. Date Filed/Granted Status Patent Number Note Australia 2011322482 06/07/2017 Granted 2,011,322,482 Australia 2017204267 05/09/2019 Granted 2,017,204,267 Canada 2,847,197 28/02/2014 Filed Europe 11779628.4 The European patent valid or being validated in: 20/02/2019 Granted E-1075071 Austria 12/02/2019 Granted 2,362,446 Belgium 14/02/2019 Granted 60 2011 054 785.2 Germany 07/03/2019 Granted 2,362,446 Finland 09/01/2019 Granted 2,362,446 France 07/03/2019 Granted 2,362,446 Iceland 02/01/2019 Granted 2362446-IE Ireland 11/03/2019 Granted 502,019,000,019,925 Italy 12/02/2019 Granted 2,362,446 Netherlands 28/02/2019 Granted 2,362,446 Norway 11/03/2019 Filed Spain 28/02/2019 Granted 2,362,446 Sweden 26/02/2019 Granted 2,362,446 Switzerland/Liechtenstein 21/12/2018 Granted 2,362,446 United Kingdom Japan 2013-535462 16/09/2016 Granted 6004494 U.S. 16/399,547 02/06/2020 Granted 10669334 U.S. 13/882,262 22/09/2015 Granted 9,138,458 U.S. 14/852,442 30/04/2019 Granted 10273296 METHODS OF PREVENTION OR TREATMENT OF TRIGGERED INFLAMMATORY REACTIONS USING TNF ALPHA ANTAGONIST Country Application No. Date Granted Status Patent Number Note Europe 11710004 03/06/2020 Granted 2,547,363 Austria 03/06/2020 Granted 2547363 Belgium 03/06/2020 Granted 2547363 Switzerland 03/06/2020 Granted 602,011,067,119 Germany 03/06/2020 Granted DK/EP 2547363 Denmark 03/06/2020 Granted 2547363 Spain 03/06/2020 Granted 2547363 Finland 03/06/2020 Granted 2547363 France 03/06/2020 Granted 2547363 Ireland 03/06/2020 Granted 2547363 Italy 03/06/2020 Granted 2547363 Netherland 03/06/2020 Granted 2547363 Norway 03/06/2020 Granted 2547363 Sweden 03/06/2020 Granted 2547363 United Kingdom METHOD FOR TREATMENT OF POST OPERATIVE COGNITIVE DYSFUNCTION Country Application No. Grant Date Status Patent Number Note U.S. 13/579,555 12/04/2016 Granted 9,308,254 Japan 2012-553396 24/06/2016 Granted 5,955,227 180 Life Sciences Corp. www.180lifesciences.com Q4 2020